Wide Ranks

GLYC

GlycoMimetics, Inc.

0.3131

Top Statistics
Market Cap 20 M Forward PE -3.48 Revenue Growth 0.00 %
Current Ratio 5.48 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.0940 Enterprise / Revenue 381.76 Price To Sales Trailing12 Months 2018.99
Profitability
Profit Margins 0.00 % Operating Margins -408770.50 %
Balance Sheet
Total Cash 22 M Total Cash Per Share 0.3470 Total Debt 448775
Total Debt To Equity 2.24 Current Ratio 5.48 Book Value Per Share 0.5970
All Measures
Short Ratio 107.00 % Message Board Id finmb_5703481 Fax 301 738 2137
Shares Short Prior Month 1 M Return On Equity -1.04 City Rockville
Uuid efe04473-e4ee-3464-8e89-48cc4b8490b8 Previous Close 0.3210 First Trade Date Epoch Utc 1 B
Book Value 0.5970 Beta 1.84 Total Debt 448775
Volume 875714 Price To Book 0.5245 Fifty Two Week Low 0.1400
Total Cash Per Share 0.3470 Total Revenue 10000 Shares Short Previous Month Date 1 B
Target Median Price 1.00 Audit Risk 8 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -408770.50 % Target Mean Price 1.00
Net Income To Common -39113232 Short Percent Of Float 0.1261 Implied Shares Outstanding 66 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 22 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0312 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 9 Regular Market Previous Close 0.3210
Target Low Price 1.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.2596
Open 0.3000 Free Cashflow -22150632 State MD
Dividend Yield 0.00 % Return On Assets -0.5925 Time Zone Short Name EST
Board Risk 6 Trailing Eps -0.6200 Day Low 0.2964
Address1 9708 Medical Center Drive Shares Outstanding 64 M Compensation Risk 7
Price Hint 4 Target High Price 1.00 Website https://www.glycomimetics.com
52 Week Change -0.8110 Average Volume 19 M Forward Eps -0.0900
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 515.60 %
Is_sp_500 False Regular Market Day High 0.3271 Profit Margins 0.00 %
Debt To Equity 2.24 Fifty Two Week High 3.53 Day High 0.3271
Shares Short 5 M Regular Market Open 0.3000 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 381.76 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0874 Operating Cashflow -35700392 Currency USD
Time Zone Full Name America/New_York Market Cap 20 M Is_nasdaq_100 False
Zip 20850 Quote Type EQUITY Industry Biotechnology
Long Name GlycoMimetics, Inc. Overall Risk 7 Regular Market Day Low 0.2964
Held Percent Institutions 0.4791 Current Price 0.3131 Enterprise To Ebitda -0.0940
Financial Currency USD Current Ratio 5.48 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 42 M Two Hundred Day Average 0.9034 Governance Epoch Date 1 B
Enterprise Value 3 M Price To Sales Trailing12 Months 2018.99 Forward PE -3.48
Regular Market Volume 875714 Ebitda -40783964 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.

It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.

The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.

In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma.

The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.

GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.